Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Olokizumab

Aliases
Olokizumab 64mg q2w, Olokizumab 64mg q4w

7 clinical trials

2 indications

Indication
COVID-19
Indication
Rheumatoid Arthritis
Clinical trial
A Multicenter, Open-label, Randomized Study of the Efficacy and Safety of Artlegia (INN: Olokizumab) New Dosing Regimen in Patients With Coronavirus Infection (COVID-19) With Signs of Hyperinflammation
Status: Active (not recruiting), Estimated PCD: 2022-10-31
Clinical trial
A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4
Status: Completed, Estimated PCD: 2022-06-08
Clinical trial
Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
Status: Completed, Estimated PCD: 2022-08-29
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Status: Completed, Estimated PCD: 2018-08-01
Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Status: Completed, Estimated PCD: 2019-09-12
Clinical trial
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Status: Completed, Estimated PCD: 2019-08-02